Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 5121-5126

  Furukawa, Kenei ^a   Uwagawa, Tadashi ^a   Iwase, Ryota ^a   Haruki, Koichiro ^a   Fujiwara, Yuki ^a   Gocho, Takeshi ^a   Shiba, Hiroaki ^a   Misawa, Takeyuki ^a   Yanaga, Katsuhiko ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Gemcitabine; Nafamostat mesilate; Prognosis; Unresectable pancreatic cancer

Indexed keywords

C REACTIVE PROTEIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GEMCITABINE; NAFAMSTAT MESILATE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASCITES; BACKACHE; BILIARY TRACT DRAINAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOMATOSIS; CLINICAL ARTICLE; DIABETES MELLITUS; DISTANT METASTASIS; FATIGUE; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER METASTASIS; LUNG METASTASIS; LYMPHOCYTE COUNT; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; GUANIDINES; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84872663500     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Niederhuber JE, Brennan MF and Menck HR: The National Cancer Date Base report on pancreatic cancer. Cancer 76: 1671-1677, 1995.
2. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD and Von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15: 2403-2413, 1997.
3. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG and Benson AB 3rd: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275, 2002.
4. Chen F, Castranova V and Shi X: New insights into the role of nuclear factor-κB in cell growth regulation. Am J Pathol 159: 387-397, 2001.
5. Amer BA and David B: An essential role for NF-κB in preventing TNF-alpha-induced cell death. Science 274: 782-784, 1996.
6. Antwerp VDJ, Seamus MJ, Tal K, Douglas GR and Inder VM: Suppression of TNF-alpha-induced apoptosis by NF-κB. Science 274: 787-789, 1996.
7. Karin M and Lin A: NF-κB at the crossroads of life and death. Nature Immunol 3: 221-227, 2002.
8. Huang S, Robinson JB, DeGuzman A, Bucana CD and fiddler IJ: Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60: 5334-5339, 2000.
9. Matsumoto G, Namekawa J, Muta M, Nakamura T, Bando H, Tohyama K, Toi M and Umezawa K: Targeting of nuclear factor eκB pathways by dehydroxymethyleoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin Cancer Res 11: 1287-1293, 2005.
10. Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, Takahashi N, Shima Y, Umezawa K and Kurai M: Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res 63: 107-110, 2003.
11. Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ: Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197, 2001.
12. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR and Chiano PJ: The nuclear factor-κB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119-127, 1999.
13. Wang W, Abbruzzese JL, Evans DB and Chiano PJ: Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regurated by constitutively activated RelA. Oncogene 18: 4554-4563, 1999.
14. Fujioka S, Sclabas GM, Schmidit C, Niu J, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C and Chiao PJ: Inhibition of constitutive NF-κB activity by I κBαM suppresses tumorigenesis. Oncogene 22: 1365-1370, 2003.
15. Fujioka S, Sclabas GM, Schmidit C, Frederick WA, Dong QG, Abbruzzese JL, Evans DB, Baker C and Chiao PJ: Function of nuclear κB in pancreatic cancer metastasis. Clin Cancer Res 9: 346-354, 2003.
16. Fujii S and Hitomi Y: New synthetic inhibitors of C1r, C1 esterase, thrombin, kallikrein and trypsin. Biochimi Biophys Acta 661: 342-345, 1981.
17. Aoyama T, Ino Y, Ozeki M, Oda M, Sato T, Koshiyama Y, Suzuki S and Fujita M: Pharmacological studies of FUT-175, nafamostat mesilate. I. Inhibition of protease avtivity in in vitro and in vivo experiments. Jpn J Pharmacol 35: 207-227, 1984.
18. Iwaki M, Ino Y, Motoyoshi A, Ozeki M, Sato T, Kurumi M and Aoyama T: Pharmacological studies of FUT-175, nafamostat mesilate. V. Effects on pancreatic enzymes and experimental acute pancreatitis in rats. Jpn J Phamacol 41: 155-162, 1986.
19. Takahashi H, Takizawa S, Tatewaki W, Nagai K, Wada K, Hanano M and Shibata A: Nafamostat mesilate (FUT-175) in the treatment of patients with disseminated intravascular coagulations. Thomb Haemost 62: 372, 1989.
20. Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, Matsuda K and Kitamura N: Nafamostat mesilate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contr Nephrol 93: 215-7, 1991.
21. Uwagawa T, Li Z, Chang Zhe, Xia Q, Peng B, Sclabas GM, Ishiyama S, Hung MC, Evans DB, Abbruzzese JL and Chiao PJ: Mechanisms of synthetic serine protease inhibitor (FUT-175)-mediated cell death. Cancer 109: 2142-2153, 2007.
22. Furukawa K, Iida T, Shiba H, Fujiwara Y, Uwagawa T, Shimada Y, Misawa T, Ohashi T and Yanaga K: Anti-tumor effect by inhibition of NF-κB activation using nafamostat mesilate for pancreatic cancer in a mouse model. Oncol Rep 24 : 843-50, 2010.
23. Uwagawa T, Chiano PJ, Gocyo T, Hirohara S, Misawa T and Yanaga K: Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-κB activation. Anticancer Res 29: 3173-3178, 2009.
24. Uwagawa T, Misawa T, Sakamoto T, Ito R, Gocho T, Shiba H, Wakiyama S, Hirohara S, Sadaoka S and Yanaga K: A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Ann Oncol 20: 239-243, 2009.
25. Uwagawa T, Misawa T, Tsutsui N, Ito R, Gocho T, Hirohara S, Sadaoka S, Yanaga K. Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer. Am J Clin Oncol 2011.
26. Park JK, Yoon YB, Kim YT, Ryu JK, Yoon WJ and Lee SH: Survival and prognostic factors of unresectable pancreatic cancer. J Clin Gastroenterol 42: 86-91, 2008.
27. Papadoniou N, Kosmas C, Gennatas K, Polyzos A, Mouratidou D, Skopelitis E, Tzivras M, Sougioultzis S, Papastratis G, Karatzas G, Papalambros E and Tsavaris N: Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: A retrospective analysis. Anticancer Res 28: 543-549, 2008.
28. Weber A, Kehl V, Mittermeyer T, Herberich E, Röthling N, Schmid RM and Prinz C: Prognostic factors for survival in patients with unresectable pancreatic cancer. Pancreas 39: 1247-1253, 2010.
29. Yi JH, Lee J, Park SH, Lee KT, Lee JK, Lee KH, Choi DW, Choi SH, Heo JS, Lim do H, Park YS, Lim HY, Kang WK, Park K and Park JO: A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer. Oncology 80 : 175-180, 2011.
30. Fujiwara Y, Furukawa K, Haruki K, Shimada Y, Iida T, Shiba H, Uwagawa T, Ohashi T and Yanaga K: Nafamostat mesilate can prevent adhesion, invasion and peritoneal dissemination of pancreatic cancer thorough nuclear factor-kappa B inhibition. J Hepatobiliary Pancreat Sci 18: 731-739, 2011.
31. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C and Ducreux M; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825, 2011.
32. + tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas 28: e26-31, 2004.
33. + T-lymphocytes into effector CTL. J Immunol 172: 6558-6567, 2004.
34. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, Pedrazzoli S and Plebani M: Decreased total lymphocyte counts in pancreatic cancer: An index of adverse outcome. Pancreas 32: 22-28, 2006.
35. Pahl HL: Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18: 6853-6866, 1999.